AstraZeneca says its COVID-19 vaccine is 79 percent effective in large U.S. trial
AstraZeneca and Oxford University said Monday that their COVID-19 vaccine proved to be 79 percent effective against symptomatic illness and 100 percent effective at preventing serious COVID-19 cases or hospitalization in a U.S. trial involving more than 30,000 people. The vaccine, tested on 32,559 people 18 and older was effective among all age groups and demographics, including 80 percent effective with participants 65 and older.
The U.S. trial's independent safety monitors, aided by an outside neurologist, specifically reviewed the trail data for increased risk of severe blood clotting, following reports of vaccinated people in Europe suffering from cerebral venous sinus thrombosis. The review found no increased risk of thrombosis in the 21,583 volunteers who received at least one dose of the vaccine; the other participants were given a placebo.
A YouGov poll published Monday found that a growing number of adults in Spain, Germany, France, and Italy believe the AstraZeneca vaccine is unsafe, following a brief suspension of the vaccine in those countries last week. They began using the vaccine again after the European Medicines Agency and World Health Organization affirmed that AstraZeneca's vaccine is safe and effective.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Public confidence in this vaccine, developed by Oxford researchers, is especially important for the global vaccination effort. The vaccine is already the most-used shot in many countries, and largely because of its price — about $4 a dose — and ability to be stored in a normal refrigerator, it is central to the efforts to vaccinate the developing world.
The U.S. has also ordered 300 million doses, though the Food and Drug Administration has not yet given it emergency use authorization. AstraZeneca said Monday it will submit the full results of its U.S. trial to the FDA and for peer review to be published in a journal.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
The week's best photos
In Pictures Playful goslings, an exploding snowman, and more
By Anahi Valenzuela, The Week US Published
-
What is rock flour and how can it help to fight climate change?
The Explainer Glacier dust to the rescue
By Devika Rao, The Week US Published
-
Crossword: April 19, 2024
The Week's daily crossword puzzle
By The Week Staff Published
-
Post Office's Capture software to be reviewed over 'glitches'
Speed Read Solicitor representing accused postmasters says flaws in the IT system follow 'very similar pattern' to Horizon
By Arion McNicoll, The Week UK Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published
-
Disney board fends off Peltz infiltration bid
Speed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
By Rafi Schwartz, The Week US Published
-
Disney and DeSantis reach detente
Speed Read The Florida governor and Disney settle a yearslong litigation over control of the tourism district
By Peter Weber, The Week US Published
-
Visa and Mastercard agree to lower swipe fees
Speed Read The companies will cap the fees they charge businesses when customers use their credit cards
By Peter Weber, The Week US Published
-
Reddit IPO values social media site at $6.4 billion
Speed Read The company makes its public debut on the New York Stock Exchange
By Peter Weber, The Week US Published
-
Housing costs: the root of US economic malaise?
speed read Many voters are troubled by the housing affordability crisis
By Peter Weber, The Week US Published